

UNITED STATE DEPARTMENT OF COMMERCE

Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

ATTORNEY DOCKET NO. FIRST NAMED INVENTOR FILING DATE APPLICATION NO. Н STENDER 10/03/97 08/943,777 **EXAMINER** Г HM22/0701 FREDMAN, J JESSE REINGOLD PAPER NUMBER ART UNIT GRAHAM & JAMES 24TH FLOOR 1655 885 THIRD AVENUE NEW YORK NY 10022 DATE MAILED: 07/01/99

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Application No. 08/943,777

Office Action Summary

Applica

Stender et al

Examiner

Jeffrey Fredman

Group Art Unit 1655



Responsive to communication(s) filed on	
☐ This action is FINAL .	
Since this application is in condition for allowance except for f in accordance with the practice under <i>Ex parte Quayle</i> , 1935	C.D. 11, 433 C.G. 210.
A shortened statutory period for response to this action is set to is longer, from the mailing date of this communication. Failure to application to become abandoned. (35 U.S.C. § 133). Extension 37 CFR 1.136(a).	
Disposition of Claims	is/are pending in the application.
	is/are pending in the application.
Of the above, claim(s)	is/are withdrawn from consideration.
Claim(s)	is/are allowed.
☐ Claim(s)	is/are rejected.
Claim(s)	is/are objected to.
	are subject to restriction or election requirement.
 ☐ The drawing(s) filed on	under 35 U.S.C. § 119(a)-(d). f the priority documents have been mber) International Bureau (PCT Rule 17.2(a)).
Attachment(s) Notice of References Cited, PTO-892 Information Disclosure Statement(s), PTO-1449, Paper Notice of Draftsperson's Patent Drawing Review, PTO-94 Notice of Informal Patent Application, PTO-152	
SEE OFFICE ACTION ON	THE FOLLOWING PAGES

Serial Number: 08/943,777 Page 2

Art Unit: 1655

DETAILED ACTION

Sequence Rules

1. This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 due to the absence of a CRF and paper copy for the SEQ ID NOs listed in the claims. Please see the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. A complete response to this action will require compliance with the Sequence Rules.

Election/Restriction

- 2. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 1-24, 35 and 36, drawn to PNA probes, classified in class 536, subclass 24.3.
 - II. Claims 25-34, drawn to methods of Mycobacteria detection, classified in class 435,subclass 6.
- 3. The inventions are distinct, each from the other because of the following reasons:

 Inventions in Group I and in Group II are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP)

٥

Serial Number: 08/943,777

Art Unit: 1655

§ 806.05(h)). In the instant case, the PNA probes of Group I can be used in detection methods of Group II, in amplification methods, in antisense therapy methods, in nucleic acid purification methods or in gene therapy methods.

- 4. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.
- 5. A telephone call was made to Jesse Reingold on September 14, 1998 to request an oral election to the above restriction requirement, but did not result in an election being made.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

- 6. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).
- 7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jeff Fredman, Ph.D. whose telephone number is (703) 308-6568.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, W. Gary Jones, can be reached on (703) 308-1152.

Serial Number: 08/943,777

Art Unit: 1655

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Papers related to this application may be submitted to Group 180 by facsimile transmission via the P.T.O. Fax Center located in Crystal Mall 1. The CM1 Fax Center numbers for Group 1800 are either (703) 305-3014 or (703) 308-4242. Please note that the faxing of such papers must conform with the Notice to Comply published in the Official Gazette, 1096 OG 30 (November 15, 1989).

Jeffrey Fredman Primary Patent Examiner Art Unit 1655

June 30, 1999